4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Syndax Pharmaceuticals, Inc. (SNDX) operates in the Biotechnology industry and is headquartered in New York, United States with about 298 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SNDX reported $172M in revenue and ($285M) in net income.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Interactive charts & full statements → Open the SNDX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $172M | $24M | $0M | $0M | — |
| Gross Profit | $165M | $23M | $0M | $0M | — |
| Operating Income (EBIT) | ($273M) | ($340M) | ($230M) | ($152M) | — |
| Net Income | ($285M) | ($319M) | ($209M) | ($149M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $65M | $69M | $46M | $38M | $20M |
| Gross Profit | $62M | $66M | $44M | $37M | $19M |
| Operating Income (EBIT) | ($34M) | ($62M) | ($57M) | ($69M) | ($84M) |
| Net Income | ($43M) | ($68M) | ($61M) | ($72M) | ($85M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $530M | $725M | $613M | $497M | — |
| Total Liabilities | $465M | $437M | $59M | $30M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SNDX viewer.
About TickerBase · Data methodology & sources